Original Articles
Copyright ©The Author(s) 2001. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 15, 2001; 7(1): 22-27
Published online Feb 15, 2001. doi: 10.3748/wjg.v7.i1.22
Reduction of tumorigenicity of SMMC-27721 hepatoma cells by vascular endothelial growth factor antisense gene therapy
Yu Cheng Tang, Yu Li, Guan Xiang Qian
Yu Cheng Tang, Yu Li, Guan Xiang Qian, Department of Biochemistry, Shanghai Second Medical University, Shanghai 200025, China
Yu Cheng Tang, graduated in 2000 from Shanghai Second Medical University, specialized in tumor biology.
Author contributions: All authors contributed equally to the work.
Supported by National Natural Science Foundation of China, No.863-Z20-01-04
Correspondence to: Yu Cheng Tang, Department of Biochemistry, Shanghai Second Medical University, Shanghai 200025, China. tangyc@shsmu.edu.cn
Telephone: 0086-21-63846590 Ext. 504 Fax: 0086-21-63842916
Received: September 21, 2000
Revised: October 22, 2000
Accepted: October 29, 2000
Published online: February 15, 2001
Abstract

AIM: To test the hypothesis to block VEGF expression of SMMC-7721 hepatomacells may inhibit tumor growth using the rat hepatoma model.

METHODS: Amplifiy the 200 VEGF cDNA fragment and insert it into human U6 gene cassette in the reverse orientation transcribing small antisense RNA which could specifically interact with VEGF165, and VEGF121 mRNA. Construct the retroviral vector containing this antisense VEGF U6 cassette and package the replication-deficient recombinant retrovirus. SMMC-7721 cells were transduced with these virus and positive clones were selected with G418. PCR and Southern blot analysis were performed to determine if U6 cassette integrated into the genomic DNA of positive clone. Transfected tumor cells were evaluated for RNA expression by ribonuclease protection assays. The VEGF protein in the supernatant of parental tumor cells and genetically modified tumor cells was determined with ELISA. In vitro and in vivo growth properties of antisense VEGF cell clone in nude mice were analyzed.

RESULTS: Restriction enzyme digestion and PCR sequencing verified that the antisense VEGF RNA retroviral vector was successfully constructed. After G418 selection, resistant SMMC-7721 cell clone was picked up. PCR and Southern blot analysis suggested that U6 cassette was integrated into the cell genomic DNA. Stable SMMC-7721 cell clone transduced with U6 antisense RNA cassette could express 200 bp small antisense VEGF RNA and secrete reduced levels of VEGF in culture condition. Production of VEGF by antisense transgenea2expressing cells was 65 ± 10 ng/L per 106 cells, 420 ± 45 ng/L per 106 cells in sense group and 485 ± 30 ng/ L per 106 cells in the negative control group, (P < 0.5). The antisense-VEGF cell clone appeared phenotypically indistinguishable from SMMC-7721 cells and SMMC-7721 cells transfected sense VEGF. The growth rate of the antisense-VEGF cell clone was the same as the control cells. When S.C. was implanted into nude mice, growth of antisense-VEGF cell lines was greatly inhibited compared with control cells.

CONCLUSION: Expression of antisense VEGF RNA in SMMC-7721 cells could decrease the tumorigenicity, and antisense-VEGF gene therapy may be an adjuvant treatment for hepatoma.

Keywords: liver neoplasms, endothelial growth factors, gene therapy, endothelium vascular, enzymea2linked immunosorbent assay, carcinoma, hepatocellular, RNA, antisense